Related Experiment Video
Updated: Oct 14, 2025
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
Published on: April 4, 2019
Exchange Protein Directly Activated by cAMP 2 Enhances Respiratory Syncytial Virus-Induced Pulmonary Disease in Mice
Junping Ren1, Wenzhe Wu1, Ke Zhang1,2
1Department of Pediatrics, University of Texas Medical Branch, Galveston, TX, United States.
Insights
Respiratory syncytial virus (RSV) causes significant respiratory illness. Targeting the EPAC2 protein pathway in mice reduced RSV symptoms, suggesting EPAC2 as a potential therapeutic target for RSV infections.
Area of Science:
- Virology
- Immunology
- Pulmonology
Background:
- Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children.
- High-risk populations face severe morbidity and mortality from RSV, yet no specific treatment exists.
- The exchange protein directly activated by cyclic AMP 2 (EPAC2) has been identified as a potential therapeutic target for RSV.
Purpose of the Study:
- To investigate the role of EPAC2 in pulmonary responses during experimental RSV infection.
- To evaluate EPAC2 as a therapeutic target for mitigating RSV-induced airway disease.
Main Methods:
- Utilized EPAC2-deficient (KO) mice and wild-type (WT) mice in an experimental RSV infection model.
- Administered an EPAC2-specific inhibitor to a separate cohort of mice.
- Assessed body weight loss, airway hyperresponsiveness, and pulmonary inflammation as key outcome measures.
Main Results:
- EPAC2-deficient mice and mice treated with an EPAC2 inhibitor exhibited significantly reduced body weight loss compared to controls.
- Airway hyperresponsiveness and pulmonary inflammation were markedly decreased in EPAC2-deficient or inhibited mice.
- These findings highlight EPAC2's role in promoting RSV-related pathology.
Conclusions:
- The EPAC2-mediated pathway critically contributes to airway diseases associated with experimental RSV infection.
- Targeting EPAC2 presents a promising therapeutic strategy for managing RSV infections and their pulmonary complications.
Abstract:
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in young children. It is also a significant contributor to upper respiratory tract infections, therefore, a major cause for visits to the pediatrician. High morbidity and mortality are associated with high-risk populations including premature infants, the elderly, and the immunocompromised. However, no effective and specific treatment is available. Recently, we discovered that an exchange protein directly activated by cyclic AMP 2 (EPAC2) can serve as a potential therapeutic target for RSV. In both lower and upper epithelial cells, EPAC2 promotes RSV replication and pro-inflammatory cytokine/chemokine induction. However, the overall role of EPAC2 in the pulmonary responses to RSV has not been investigated. Herein, we found that EPAC2-deficient mice (KO) or mice treated with an EPAC2-specific inhibitor showed a significant decrease in body weight loss, airway hyperresponsiveness, and pulmonary inflammation, compared with wild-type (WT) or vehicle-treated mice. Overall, this study demonstrates the critical contribution of the EPAC2-mediated pathway to airway diseases in experimental RSV infection, suggesting the possibility to target EPAC2 as a promising treatment modality for RSV.
